ProMetic Life Sciences Inc. (TSE:PLI) – Stock analysts at National Bank Financial reduced their FY2017 earnings per share (EPS) estimates for shares of ProMetic Life Sciences in a research report issued on Tuesday. National Bank Financial analyst E. Leno now forecasts that the company will post earnings of ($0.14) per share for the year, down from their previous forecast of ($0.12). National Bank Financial also issued estimates for ProMetic Life Sciences’ FY2018 earnings at ($0.09) EPS.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2017/08/18/prometic-life-sciences-inc-expected-to-earn-fy2017-earnings-of-0-14-per-share-pli.html.

PLI has been the topic of several other reports. Canaccord Genuity dropped their price target on ProMetic Life Sciences from C$4.75 to C$4.50 and set a “buy” rating on the stock in a research report on Monday, June 19th. Royal Bank Of Canada reissued an “outperform” rating on shares of ProMetic Life Sciences in a report on Wednesday, May 24th. Scotiabank dropped their target price on ProMetic Life Sciences from C$4.75 to C$4.00 and set an “outperform” rating on the stock in a report on Friday, July 7th. Finally, TD Securities dropped their target price on ProMetic Life Sciences from C$4.50 to C$3.50 and set a “speculative buy” rating on the stock in a report on Wednesday. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of C$4.07.

ProMetic Life Sciences (TSE PLI) opened at 1.17 on Friday. The company has a 50 day moving average price of $1.55 and a 200-day moving average price of $2.00. ProMetic Life Sciences has a one year low of $1.13 and a one year high of $3.24. The company’s market capitalization is $826.07 million.

In other ProMetic Life Sciences news, Director Louise Ménard sold 82,202 shares of the business’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of C$1.60, for a total value of C$131,523.20. Insiders acquired 35,624 shares of company stock worth $56,505 over the last three months.

About ProMetic Life Sciences

ProMetic Life Sciences Inc, a biopharmaceutical company, develops bioseparations, plasma-derived therapeutics, and small-molecule therapeutic products. The company offers its technology platform for large-scale drug purification, drug development, proteomics, and the elimination of pathogens; and develops small molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, autoimmune disease/inflammation, and cancer.

Earnings History and Estimates for ProMetic Life Sciences (TSE:PLI)

Receive News & Ratings for ProMetic Life Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.